Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIY6DB)

• Drug Name: Verteporfin Drug Info
• Synonyms: Visudyne (TN)

Indication

Disease Entry	ICD 11	Status	REF
Choroidal neovascularization	9B76	Approved	[1]
Exudative age-related macular degeneration	9B78.3Z	Approved	[1]
Psoriasis vulgaris	EA90	Approved	[2]

• Cross-matching ID:
  PubChem CID: 11980904
  TTD Drug ID: DMIY6DB
  VARIDT Drug ID: DR00209

Molecule-Related Drug Atlas

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[5]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[6]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[7]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[8]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[9]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[10]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[11]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[10]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[12]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[13]

Drug(s) Transported By ATP-binding cassette sub-family B member 6 (ABCB6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tomatine	DMA3U15	N. A.	N. A.	Investigative	[3]

Molecular Interaction Atlas of This Drug

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
ATP-binding cassette sub-family B member 6 (ABCB6)	DTF9Y2V	ABCB6_HUMAN	Substrate	[3]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[4]

References

• [1] Verteporfin FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Efficient purification and reconstitution of ATP binding cassette transporter B6 (ABCB6) for functional and structural studies. J Biol Chem. 2013 Aug 2;288(31):22658-69.
• [4] The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007 Apr 15;13(8):2463-70.
• [5] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [6] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [7] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [8] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [9] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [10] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [11] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [12] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [13] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.